Table 1.

Association of demographic and clinicopathological variables with performance of Oncotype DX

		No	%	Yes	%	Risk ratio	95% CI lower	95% CI upper	P‐value
		n = 5182		n = 446
Race
Caucasian		3964	76.5%	400	89.7%
African American		1218	23.5%	46	10.3%	0.402	0.2994	0.5407	<0.001
Grade 2
I		1126	21.7%	141	31.6%
II		2177	42.0%	226	50.7%	0.8451	0.6926	1.0312	0.11
III		1879	36.3%	79	17.7%	0.3626	0.2524	0.4466	<0.001
Stage
Stage 1		2598	50.1%	296	66.4%
Stage 2		1677	32.4%	129	28.9%	0.5989	0.4908	0.7308	<0.001
Stage 3		665	12.8%	18	4.0%	0.2577	0.1613	0.4116	<0.001
Stage 4		242	4.7%	1	1.2%	0.0402	0.0057	0.2853	<0.001
Estrogen receptor status
Positive		3904	75.3%	419	93.9%
Negative		1278	24.7%	27	6.1%	0.21	0.01454	0.3135	<0.001
Progesterone receptor status
Positive		3401	65.6%	381	85.4%
Negative		1781	34.4%	65	14.6%	0.3495	0.2703	0.452	<0.001
HER2 status
Not amplified		4208	85.1%	413	95.8%
Amplified		736	14.9%	18	4.2%	0.2671	0.1677	0.4255	<0.001
Hormone receptor status
ER and PR positive		3319	64.0%	381	85.4%
ER or PR positive		667	12.9%	38	8.5%	0.2609	0.1543	0.441	<0.001
Double negative		1196	23.1%	27	6.1%	0.209	0.1423	0.307	<0.001
Subtype (Only in patients with ER, PR, and HER2 data)
Luminal A		3303	66.8%	392	91.0%
Luminal B		494	10.0%	14	3.2%	0.2598	0.1537	0.4391	<0.001
HER2 overexpressing		242	4.9%	4	0.9%	0.1533	0.0577	0.4069	<0.001
Triple negative		905	18.3%	21	4.9%	0.2138	0.1386	0.3296	<0.001

ER, estrogen receptor; PR, progesterone receptor.